The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials
Open accessAbstract
Importance: Health outcomes from the Women's Health Initiative Estrogen Plus Progestin and Estrogen-Alone Trials have been reported, but previous publications have generally not focused on all-cause and cause-specific mortality. Objective: To examine total and cause-specific cumulative mortality, including during the intervention and extended postintervention follow-up, of the 2 Women's Health Initiative hormone therapy trials. Design, Setting, and Participants: Observational follow-up of US multiethnic postmenopausal women aged 50 to 79 years enrolled in 2 randomized clinical trials between 1993 and 1998 and followed up through December 31, 2014. Interventions: Conjugated equine estrogens (CEE, 0.625 mg/d) plus medroxyprogesterone acetate (MPA, 2.5 mg/d) (n = 8506) vs placebo (n = 8102) for 5.6 years (median) or CEE alone (n = 5310) vs placebo (n = 5429) for 7.2 years (median). Main Outcomes and Measures: All-cause mortality (primary outcome) and cause-specific mortality (cardiovascular disease mortality, cancer mortality, and other major causes of mortality) in the 2 trials pooled and in each trial individually, with prespecified analyses by 10-year age group based on age at time of randomization. Results: Among 27 347 women who were randomized (baseline mean [SD] age, 63.4 [7.2] years; 80.6% white), mortality follow-up was available for more than 98%. During the cumulative 18-year follow-up, 7489 deaths occurred (1088 deaths during the intervention phase and 6401 deaths during postintervention follow-up). All-cause mortality was 27.1% in the hormone therapy group vs 27.6% in the placebo group (hazard ratio [HR], 0.99 [95% CI, 0.94-1.03]) in the overall pooled cohort; with CEE plus MPA, the HR was 1.02 (95% CI, 0.96-1.08); and with CEE alone, the HR was 0.94 (95% CI, 0.88-1.01). In the pooled cohort for cardiovascular mortality, the HR was 1.00 (95% CI, 0.92-1.08 [8.9 % with hormone therapy vs 9.0% with placebo]); for total cancer mortality, the HR was 1.03 (95% CI, 0.95-1.12 [8.2 % with hormone therapy vs 8.0% with placebo]); and for other causes, the HR was 0.95 (95% CI, 0.88-1.02 [10.0% with hormone therapy vs 10.7% with placebo]), and results did not differ significantly between trials. When examined by 10-year age groups comparing younger women (aged 50-59 years) to older women (aged 70-79 years) in the pooled cohort, the ratio of nominal HRs for all-cause mortality was 0.61 (95% CI, 0.43-0.87) during the intervention phase and the ratio was 0.87 (95% CI, 0.76-1.00) during cumulative 18-year follow-up, without significant heterogeneity between trials. Conclusions and Relevance: Among postmenopausal women, hormone therapy with CEE plus MPA for a median of 5.6 years or with CEE alone for a median of 7.2 years was not associated with risk of all-cause, cardiovascular, or cancer mortality during a cumulative follow-up of 18 years. Trial Registration: clinicaltrials.gov Identifier: NCT00000611.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Design of the Women’s Health Initiative Clinical Trial and Observational Study
(1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,585
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Self-citationPostmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741
Self-citationManson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., et al. (2013) · JAMA · doi:10.1001/jama.2013.278040 · Cited by 1,650
Self-citationShumaker, S. A. (2004) · JAMA · doi:10.1001/jama.291.24.2947 · Cited by 1,366
Self-citationPostmenopausal Hormone Therapy and Mortality
Grodstein, F., Stampfer, M. J., Colditz, G. A., Willett, W. C., Manson, J. E., Joffe, M., Rosner, B., Fuchs, C., Hankinson, S. E., Hunter, D. J., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706193362501 · Cited by 1,184
Self-citationMolecular and Cellular Basis of Cardiovascular Gender Differences
Mendelsohn, M. E., & Karas, R. H. (2005) · Science · doi:10.1126/science.1112062 · Cited by 1,101
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
The 2012 Hormone Therapy Position Statement of The North American Menopause Society
(2012) · Menopause · doi:10.1097/gme.0b013e31824b970a · Cited by 785
Vascular effects of early versus late postmenopausal treatment with estradiol
Hodis, H. N., Mack, W. J., Henderson, V. W., Shoupe, D., Budoff, M. J., Hwang-Levine, J., Li, Y., Feng, M., Dustin, L., Kono, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505241 · Cited by 779
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N., Braunstein, G. D., Burger, H. G., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 680
Self-citationDecreased Mortality in Users of Estrogen Replacement Therapy
Henderson, B. E. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400010095012 · Cited by 632
for the Women’s Health Initiative Investigators, Margolis, K. L., Bonds, D. E., Rodabough, R. J., Tinker, L., Phillips, L. S., Allen, C., Bassford, T., Burke, G., Torrens, J., et al. (2004) · Diabetologia · doi:10.1007/s00125-004-1448-x · Cited by 599
Self-citationStefanick, M. L., Anderson, G. L., Margolis, K. L., Hendrix, S. L., Rodabough, R. J., Paskett, E. D., Lane, D. S., Hubbell, F. A., Assaf, A. R., Sarto, G. E., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1647 · Cited by 571
Self-citationLaCroix, A. Z. (2011) · JAMA · doi:10.1001/jama.2011.382 · Cited by 538
Self-citationTest of the National Death Index and Equifax Nationwide Death Search
Rich-Edwards, J. W., Corsano, K. A., & Stampfer, M. J. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117191 · Cited by 530
Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer
Kim, J. J., Kurita, T., & Bulun, S. E. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1043 · Cited by 520
Effects of Estrogen With and Without Progestin on Urinary Incontinence
Hendrix, S. L. (2005) · JAMA · doi:10.1001/jama.293.8.935 · Cited by 509
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Chlebowski, R. T., Kuller, L. H., Prentice, R. L., Stefanick, M. L., Manson, J. E., Gass, M., Aragaki, A. K., Ockene, J. K., Lane, D. S., Sarto, G. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807684 · Cited by 472
Self-citationXu, J., Murphy, S. L., Kochanek, K. D., & Bastian, B. A. (2016) · PubMed · Cited by 425
Estrogen replacement therapy, atherosclerosis, and vascular function
Mikkola, T. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00466-7 · Cited by 420
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin
Heiss, G. (2008) · JAMA · doi:10.1001/jama.299.9.1036 · Cited by 396
Risk Factors for Vascular Dementia and Alzheimer Disease
Gorelick, P. B. (2004) · Stroke · doi:10.1161/01.str.0000143318.70292.47 · Cited by 365
Anderson, G. L., Chlebowski, R. T., Aragaki, A. K., Kuller, L. H., Manson, J. E., Gass, M., Bluhm, E., Connelly, S., Hubbell, F. A., Lane, D., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70075-x · Cited by 364
Self-citationEffect of Estrogen Therapy on Gallbladder Disease
Cirillo, D. J. (2005) · JAMA · doi:10.1001/jama.293.3.330 · Cited by 304
(2011) · Endocrine Practice · doi:10.4158/ep.17.s4.1 · Cited by 259
Bush, T. L. (1983) · JAMA · doi:10.1001/jama.1983.03330310033022 · Cited by 257
Menopause Management — Getting Clinical Care Back on Track
Manson, J. E., & Kaunitz, A. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmp1514242 · Cited by 232
Self-citationBonds, D. E., Lasser, N., Qi, L., Brzyski, R., Caan, B., Heiss, G., Limacher, M. C., Liu, J. H., Mason, E., Oberman, A., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0096-0 · Cited by 213
Chlebowski, R. T., Rohan, T. E., Manson, J. E., Aragaki, A. K., Kaunitz, A., Stefanick, M. L., Simon, M. S., Johnson, K. C., Wactawski-Wende, J., O’Sullivan, M. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0494 · Cited by 211
Self-citationFolsom, A. R., Mink, P. J., Sellers, T. A., Hong, C. P., Zheng, W., & Potter, J. D. (1995) · American Journal of Public Health · doi:10.2105/ajph.85.8_pt_1.1128 · Cited by 200
Cobin, R. H., Futterweit, W., Ginzburg, S. B., Goodman, N. F., Kleerekoper, M., Licata, A. A., Meikle, A. W., Petak, S. M., Porte, K. L., Sellin, R. V., et al. (2006) · Endocrine Practice · doi:10.4158/ep.12.3.315 · Cited by 185
Incremental direct and indirect costs of untreated vasomotor symptoms
Sarrel, P., Portman, D., Lefebvre, P., Lafeuille, M.-H., Grittner, A. M., Fortier, J., Gravel, J., Duh, M. S., & Aupperle, P. M. (2015) · Menopause · doi:10.1097/gme.0000000000000320 · Cited by 161
Chlebowski, R. T., Anderson, G. L., Sarto, G. E., Haque, R., Runowicz, C. D., Aragaki, A. K., Thomson, C. A., Howard, B. V., Wactawski‐Wende, J., Chen, C., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv350 · Cited by 121
Self-citationGoodman, N. F., Cobin, R. H., Ginzburg, S. B., Katz, I. A., Woode, D. E., Camacho, P. M., Manson, J. E., & Petak, S. M. (2011) · Endocrine Practice · doi:10.4158/ep.17.s6.1 · Cited by 118
Self-citationAccelerated cognitive decline in patients with type 2 diabetes: MRI correlates and risk factors
Reijmer, Y. D., van den Berg, E., de Bresser, J., Kessels, R. P. C., Kappelle, L. J., Algra, A., Biessels, G. J., & on behalf of the Utrecht Diabetic Encephalopathy Study Group (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1163 · Cited by 104
The Potential for Postrandomization Confounding in Randomized Clinical Trials
Manson, J. E., SHUFELT, C. L., & Robins, J. M. (2016) · JAMA · doi:10.1001/jama.2016.3676 · Cited by 54
Self-citation
Cited by
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
“2 years was not associated with an increased risk of all-cause, cardiovascular, or cancer mortality during a cumulative followup of 18 years [284].”
El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., Allison, M. A., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000912 · Cited by 1,219
Self-citationThe 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Self-citationMehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 848
Understanding the impact of sex and gender in Alzheimer’s disease: A call to action
Nebel, R. A., Aggarwal, N. T., Barnes, L. L., Gallagher, A., Goldstein, J. M., Kantarci, K., Mallampalli, M. P., Mormino, E. C., Scott, L., Yu, W. H., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.04.008 · Cited by 839
“[72] Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al.”
Metadata
- Authors
- Manson, J. E., Aragaki, A. K., Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Chlebowski, R. T., Howard, B. V., Thomson, C. A., Margolis, K. L., Lewis, C. E., Stefanick, M. L., Jackson, R. D., Johnson, K. C., Martin, L. W., Shumaker, S. A., Espeland, M. A., Wactawski-Wende, J., & for the WHI Investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-09-12
- Volume
- 318
- Issue
- 10
- Pages
- 927
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2754589635
- Cited by
- 638
- References
- 40
- FWCI
- 46.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.